Intuitive Surgical, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +25

Intuitive Surgical (ISRG): Is Its Robotic-Surgery Moat Still Untouchable?

Medical device launch AI-generated analysis

๐Ÿ“ˆ Intuitive Surgical has an installed base of 11,710 da Vinci systems by mid-2026, representing a 12% year-over-year increase.

๐Ÿ’ฐ Approximately 86% of ISRG's revenue is recurring from instruments and services tied to each surgical procedure.

๐Ÿ“ˆ Global procedures for Intuitive Surgical are growing at a rate of around 14% annually.

๐Ÿ”ง The newer da Vinci 5 system is driving utilization approximately 11% above that of older systems.

โš ๏ธ Medtronic's Hugo and Johnson & Johnson's Ottava have received US regulatory clearance, introducing direct competition.

๐Ÿฅ Competitors like Ottava utilize space-saving designs specifically targeting hospital networks reliant on Intuitive.

๐Ÿ’ธ ISRG trades at 46 times earnings, implying high expectations for continued double-digit procedure growth.

๐Ÿ“‰ The stock has fallen about 35% from its highs to roughly $395 as the market prices in competitive risks.

๐Ÿ‘ฅ 100 hedge funds held Intuitive Surgical at the end of Q2 2026, down slightly from 103 the previous quarter.

๐Ÿ“‰ Multi-million-dollar capital placements for ISRG remain sensitive to hospital budget constraints and borrowing costs.

Bullish Signals
  • Intuitive Surgical benefits from a recurring revenue model where approximately 86% of revenue comes from instruments and services tied to procedures.
  • The company has expanded its installed base to 11,710 da Vinci systems by mid-2026, up 12% in a year.
  • Global procedure volumes are growing around 14%, providing a long runway for revenue expansion.
  • The newer da Vinci 5 system is driving higher usage with utilization running about 11% above the older system.
  • High switching costs due to surgeon training and specialized instruments create a durable competitive advantage.
Risk Factors
  • Intuitive Surgical faces heavy competition for the first time from Medtronic's Hugo and Johnson & Johnson's Ottava systems.
  • New entrants with space-saving designs like Ottava target hospitals that rely on Intuitive, potentially pressuring system placements.
  • The stock trades at 46 times earnings, meaning any slowdown in placements or pricing could prompt significant valuation compression.
  • Multi-million-dollar capital placements remain sensitive to hospital budget constraints and rising borrowing costs.
Full Analysis
Intuitive Surgical (ISRG) maintains a dominant position in robotic surgery with its da Vinci system, which has achieved an installed base of 11,710 units by mid-2026. Approximately 86% of the company's revenue is recurring, derived from instruments, accessories, and services tied to each procedure, providing a steady earnings stream as global procedures grow around 14%. The high switching costs associated with surgeon training and specialized instrument requirements reinforce its market moat. Despite a recent stock decline of roughly 35% to approximately $395, Intuitive Surgical trades at a premium valuation of 46 times earnings. Bulls argue that the company's recurring revenue model, long procedure runway, and the newer da Vinci 5 systemโ€”which drives usage 11% higher than older modelsโ€”support continued growth. Additionally, increased market adoption driven by competitors could expand the total addressable market for Intuitive. Bearish concerns focus on emerging competition from Medtronic's Hugo and Johnson & Johnson's Ottava systems, which have received US regulatory clearance. These rivals target hospital networks with space-saving designs that directly challenge Intuitive's core customer base. The market appears to be pricing in competitive risks, as any slowdown in system placements or pricing pressure could lead to further valuation compression at current multiples.